Virologic failure in people living with HIV in 1st line ART: A 10-year Mexican population-based study

Amilcar Azamar-Alonso, PhD(c)1,2, Lawrence Mbuagbaw, MD, MPH, PhD1,3, Fiona Smaill, MBChB4, Sergio A Bautista-Arredondo, MSc5, Andrew P Costa, PhD1,6,7 and Jean-Eric Tarride, PhD1,6,8,9

Abstract
Background: In Mexico, the number of people living with HIV (PLWH) receiving antiretroviral therapy (ART) has increased in the last 20 years. The elimination of a CD4 threshold to initiate publicly funded ART was a major policy implemented in 2014. The study objective was to assess the determinants of Virologic Failure (VF) in Mexican PLWH on first-line ART between 2008 and 2017 and to evaluate the effects of changes following the 2014 policy.

Methods: A 10-year patient-level data analysis was conducted using the Mexican SALVAR database. The main outcome was the proportion of PLWH with VF. A multivariable logistic regression was conducted to identify the association between covariates and VF before and after the 2014 policy implementation.

Results: We found a lower proportion of people with VF in 2014–2017 compared with 2008–2013 (50% vs 33%, p<0.001). The multivariable analysis showed a reduction in the odds of virologic failure after 2014 (Odds ratio: 0.50 [95% CI: 0.48–0.51]). Place of treatment and level of deprivation were significant predictors of VF in during 2014–2017, but not before.

Conclusion: This study indicates that, by lowering threshold levels of CD4 required for treatment initiation in Mexico, a higher number of PLWH initiated treatment during 2014–2017, compared to 2008–2013 and the odds of VF were reduced.

Keywords
HIV (Human immunodeficiency virus), Antiretroviral Therapy, Location, North America, Other, Prevention, Viral disease

Date received: 14 September 2021; revised: 10 November 2021; accepted: 29 November 2021

Introduction
The primary goal of antiretroviral therapy (ART) is to achieve and maintain virologic suppression in people living with HIV (PLWH) and to reduce disease progression and eliminate transmission through the achieving and maintaining viral suppression.1,2 It has been shown that early diagnosis and full timely access to ART reduce the probability of disease progression and improve health outcomes among PLWH.1–3 In addition to timely diagnosis and treatment, adequate monitoring and timely identification and management of treatment failure are key to reducing the clinical impact of HIV.4,5

In Mexico, the number of PLWH receiving ART has increased in the last 20 years due to different public policies focused on expanding access to ART. Starting in 2007, Mexico launched a major initiative to provide universal
access to ART conditional on several clinical criteria including CD4 counts ≤200 cells/mm³ and the presence of risk symptoms. Following the World Health Organization (WHO) recommendations for early treatment initiation of PLWH in June 2013, a major policy changed occurred when the Mexican HIV-clinical guidelines were modified in 2014 to expand universal access to ART to all PLWH irrespective of their baseline CD4 count and symptoms. The performance of the program is monitored quarterly by the government, and has shown that, on average 80% of the PLWH in Mexico show viral load (VL) counts below 50 copies/ml (virologic success) during their routine checkups. Clinical and observational studies have shown that maintaining VL under that threshold is a predictor of long-term health outcomes. Although VL is an important measure of disease progression, likelihood of transmission, and mortality, as a policy measure, it is also important to document virologic failure (VF) following first line ART treatment initiation (independently of the treatment option) at the population level. This is because VF is the result of multiple and complex factors that go beyond treatment efficacy such as poor adherence, inadequate care or access to healthcare, and other sociodemographic factors and contextual variables.

While an early study conducted in a third-level hospital in Mexico City in 2010 found that the probability of VF was 20% at 48 months after ART initiation and was higher among youth (individuals younger than 30 years old), this study was published before the 2014 changes in clinical guidelines. In addition, the determinants of VF have not been explored in Mexico and the 2014 policy changes have not been evaluated. Providing information about the proportion of PLWH with VF in Mexico, as well as the influence of changes in clinical approach for treatment initiation following the 2014 Mexican policy change will generate evidence for further HIV-policy design and implementation in Mexico and elsewhere. Therefore, the objective of this study was to document the change in rates of VF and compare the determinants of VF in Mexico before and after the updated 2014 clinical guidelines.

Methods

Study design

We performed a retrospective population-based cohort study to assess virologic failure after receiving first line treatment in PLWH in Mexico. Data were accessed using the Mexican Administrative Health Data from the Antiretroviral Administration Logistics, and Surveillance System (SALVAR in Spanish) and funded by the Mexican Ministry of Health. It contains clinical, biometric, antiretroviral therapy and demographic information of individuals enrolled in the national HIV/AIDS program. All patients provide consent for the use of personal information. Data presented in this analysis was provided to the authors as a secondary anonymized dataset. Data in SALVAR began to be captured in 2006; however, it was not until 2008 that the system was fully implemented nationwide. Currently, it contains information on more than 140,000 PLWH on ART.

Study population

For this analysis, we included adults (18 years old and older) living with HIV who received their first ART after January 1st, 2008 and before September 1st, 2017. Given the purpose of the analysis, we only considered patients that had completed at least 12 weeks of follow-up and at least three VL measures. Pregnant women, children, people who are incarcerated, and people receiving antiretroviral prophylaxis were excluded from the analyses. Individuals with incomplete information on gender, and age were also excluded.

Study outcomes

The primary outcome was the proportion of people with Virologic Failure following first line ART treatment initiation. As per the Mexican clinical guidelines definition, VF was determined by one of the following two criteria: 1) individuals without a reduction of at least one log10 of VL count at week eight compared to baseline information; and 2) individuals who had reduced at least one log10 within the first 8 weeks, but after 6 months of ART initiation presented two continuous VL measures above 200 copies/ml at any further week. However, considering WHO recommendation and in order to include more individuals in our study, we considered at least 12 weeks of follow-up instead of eight.

First line treatment was defined as the first ART components prescribed to the patient based on the information reported in SALVAR. The database also provides the specific ART assigned at treatment initiation a well as switches in ART treatments. Patients changing their first line ART from a 3-pill regimen to fewer pills (i.e., a 2 or 1-pill scheme), but maintaining the same components (i.e., efavirenz/emtricitabine/tenofovir disoproxil fumarate [EFV/FTC/TDF]) and EFV+FTC+TDF were not considered switching lines of ART treatment.

Independent variables

All variables such as gender (i.e., male, female, and trans), age (as a continuous and categorical variable), year of ART initiation, geographic information of facility (region and type of health facility), baseline virologic measures, and type of treatment were collected at the time of treatment initiation. Region was grouped following previous analysis...
on Mexican HIV population as Central East, Central West, Northwest, Northeast, and South. For our analysis, Mexico City was stratified as another region (instead of being part of Central East) based on the number of people living and receiving treatment there. Health facilities were categorized by type as Specialized Clinic CONDES (based on Mexico City), Tertiary level Hospitals or National Institutes of Health, and the Ambulatory Centers for Prevention and Attention for HIV/AIDS and Sexually Transmitted Infections (CAPASITS in Spanish). The marginalization index (high, medium, and low) estimated by the Mexican government for each Mexican municipality/location was assigned to the location of each health facility where PLWH were treated to reflect social and economic differences among health facilities.

In terms of biologic measures, CD4 cell count at first line ART treatment initiation was divided into two groups by CD4 count lower than 200 cells/mm$^3$ and higher or equal to 200 cells/mm$^3$, based on prior evidence of an association of CD4 count with VF. Baseline VL was classified as lower or equal than 100,000 copies/mL and higher than 100,000 copies/mL and was used as an adjustment for ART allocation based on clinical guidelines to reduce bias due to treatment selection. We also grouped ART as the three most used and representative first line ART available in Mexico during the studied timeframe, reported in SALVAR database for the analysis: efavirenz/tenofovir disoproxil fumarate (EFV/FTC/TDF), efavirenz + abacavir/lamivudine (EFV+ABC/3TC), boosted Protease Inhibitors + backbone (boosted PI), and other (including integrase inhibitors and all other regimens defined as a first line ART in SALVAR). Although today integrase inhibitors are an important treatment option for PLWH, their use represented less than 2% of total first line ART from 2008 to 2017 in the SALVAR database, and less than 1% before 2014. Therefore, they were included in the “other” category to avoid any estimation bias.

**Statistical analysis**

Population baseline characteristics were presented for the overall study period and separately for the periods between 2008–2013 (i.e., before policy change) and 2014–2017 (i.e., after policy change). Discrete variables were presented as percentages, while continuous variables were described in terms of mean, standard deviation (SD), median, and Inter-quartile range (IQR). Chi-Squared test for categorical variables and two-sample Welch tests for continuous variables, were used to compare the population characteristics and outcomes between the two time periods (e.g., before and after the change in policy). VF, our primary outcome, was also presented for the overall study period, by time period and by category of 1st line ART.

To identify the factors associated to VF, a multivariable logistic regression was conducted adjusting by previously mentioned variables in addition to a dichotomous variable indicating the period of policy change in 2014. Furthermore, two models were performed stratifying by time periods (2008–2013 and 2014–2017) allowing a deeper understanding of the association between covariates and the main outcomes before and after the introduction of the 2014 policy. Results are presented as Odds Ratios (OR) with a 95% confidence interval (CI). Goodness-of-fit of the logistic models was estimated using the c-statistic.

**Results**

**Study population**

SALVAR dataset contains information about first line ART of 134,860 individuals during January 2008 and September 2017. Of those, 7005 were younger than 18 years old, pregnant women or deprived of their liberty. 29,612 did not have information about VL or CD4 at treatment initiation, and 18,488 did not have at least three VL measures or established time of follow-up. The final sample shown in Figure 1 consisted of 79,755 individuals.

Comparing both periods, the age at treatment initiation was lower after 2014 (mean 34.8 vs 33.2 yo), there were fewer females (20% vs 17%, $p<0.001$), a lower proportion initiated treatment in a Hospital or National Institute (24% vs. 18%, $p<0.001$) and more in a CAPASITS (62% vs. 67%, $p<0.001$), while proportionally fewer individuals were initially treated in Mexico City and more in the South region. Marginality index showed no difference between periods. The proportion of individuals diagnosed with CD4 <200 cells/mm$^3$ was higher during 2014–2017 (12%) compared with 2008–2013 (7%). The same was seen for individuals with VL ≥ 100,000 copies/mL, although the mean log10 was lower before 2014 (4.06 vs 4.31). Treatment distribution was also different between periods: during 2008–2013 the proportion of patients with EFV/FTC/TDF was 64%, EFV+ABC/3TC was 9%, and 13% with Others; while, after 2014 this proportion changed to 68%, 15% and 8% respectively. Time from diagnosis to treatment was on average one week lower in 2014–2017 compared with 2008–2013 (median 6.98 vs 7.97 weeks). Details can be found in Table 1 for the full population and by period.

**Virologic failure**

The proportion of VF among adults who initiated treatment over the period of January 2008–September 2017 was 41%, while the proportion of PLWH with VF was lower after 2014 (50% vs 33%, $p<0.001$). Stratifying by ART, the regimens “Other” and boosted PI presented the highest proportion of people with VF (43% and 47%, respectively). However, differences were observed in the VF associated with each treatment regimens after 2014. While the “Other” category was the regimen with the highest proportion of people with VF in 2008–2013 and the lowest after 2014 (55% vs 25%, respectively, $p<0.001$) EFV/FTC/TDF had the lowest proportion before 2014 and the second highest after (47% vs 34%, $p<0.001$). Details can be found in Table 2.
Determinants of VF

Results of the multivariate logistic regression show that initiating ART during the period 2014–2017 reduced by half the odds of VF (OR=0.50 [95% CI: 0.49, 0.52]), compared to initiating treatment between 2008–2013. Other factors associated with lower likelihood of VF were being male (0.88 [95% CI: 0.85, 0.91]), older than 29 years old (e.g., 0.91 [95% CI: 0.88, 0.94 for 30–39 y.o], being diagnosed with CD4 ≥200 cells/mm³ (0.89 [95% CI: 0.85, 0.94]). In contrast, having initiated treatment in a different region than Mexico City (1.48 [95% CI: 1.36, 1.62] compared to Central East, having a first ART other than EFV/FTC/TDF (e.g., 1.22 [95% CI: 1.16, 1.28] for EFV+ABC/3TC)

Figure 1. Sample Flow for Analysis.
| Variable                        | Total | 2008–2013 | 2014–2017 | p-value |
|--------------------------------|-------|-----------|-----------|---------|
| Sample size                    | 79,755| 38,320    | 41,435    |         |
| Age Mean ± SD                  | 33.99 ± 10.26 | 34.77 ± 10.21 | 33.24 ± 10.24 | <0.001  |
| Age Median (IQR)               | 32 [26–40] | 33 [27–41] | 31 [25–39] |         |
| Age %                         |       |           |           |         |
| 18–29 yo                       | 39    | 35        | 44        | <0.001  |
| 30–39 yo                       | 34    | 36        | 32        |         |
| 40–49 yo                       | 18    | 20        | 16        |         |
| 50–59 yo                       | 7     | 2         | 6         |         |
| ≥60 yr                         | 2     | 7         | 2         |         |
| Gender %                       |       |           |           |         |
| Male                           | 80    | 79        | 82        | <0.001  |
| Female                         | 19    | 20        | 17        |         |
| Transgender                    | 1     | 1         | 1         |         |
| Health facility %              |       |           |           |         |
| Hospital/Clinic/National institute | 21     | 24        | 18        | <0.001  |
| CAPASITS                        | 65    | 62        | 67        |         |
| Specialized clinics CONDESA    | 14    | 14        | 15        |         |
| Region %                       |       |           |           |         |
| Mexico City                    | 19    | 20        | 18        | <0.001  |
| Central East                   | 31    | 31        | 31        |         |
| Central West                   | 14    | 15        | 13        |         |
| Northeast                      | 12    | 12        | 11        |         |
| Northwest                      | 8     | 8         | 9         |         |
| South                          | 16    | 14        | 18        |         |
| Marginality index %            |       |           |           |         |
| High                           | 2     | 2         | 2         | 0.135   |
| Medium                         | 1     | 1         | 1         |         |
| Low                            | 97    | 97        | 97        |         |
| Bio-markers                    |       |           |           |         |
| CD4 Mean ± SD                  | 289.74 ± 230.78 | 268.80 ± 218.31 | 308.98 ± 240.07 | <0.001  |
| CD4 Median (IQR)               | 250 [110–407] | 230 [104–372] | 271 [117–442] |         |
| CD4 <200 cells/mm³ (%)         | 10    | 7         | 12        | <0.001  |
| CD4 ≥200 cells/mm³ (%)         | 90    | 93        | 88        |         |
| VL Mean ± SD                   | 4.19 ± 1.42 | 4.06 ± 1.47 | 4.31 ± 1.35 | <0.001  |
| VL Median (log10) (IQR)        | 4.61 [3.3–5.2] | 4.55 [2.6–5.2] | 4.65 [3.7–5.2] |         |
| VL <100,000 u/ml (%)           | 63    | 63        | 62        | 0.045   |
| VL ≥100,000 u/ml (%)           | 37    | 37        | 38        |         |
| Treatment %                    |       |           |           |         |
| EFV/FTC/TDF                    | 66    | 64        | 68        | <0.001  |
| EFV+ABC/3TC                    | 12    | 9         | 15        |         |
| Boosted PI                     | 12    | 14        | 9         |         |
| Other                          | 10    | 13        | 8         |         |
| Time diagnose-treatment Mean ± SD | 42.96 ± 97.9 | 44.09 ± 94.52 | 41.92 ± 100.93 | 0.007   |
| Time diagnose-treatment Median (IQR) | 7.27 [2.1–27.1] | 7.97 [0.1–3] | 6.98 [2.8–22.5] |

Source: Authors’ contribution using SALVAR 2008–2017. Yo: years old. VL: Viral load. EFV/FTC/TDF: Emtricitabine, tenofovir, efavirenz; EFV+ABC/3TC: Abacavir, lamivudine, efavirenz.
increased the odds of having VF. Table 3 also presents the stratified analyses by time period and results indicated changes in the association with regions. Compared to Mexico City, all other Mexican regions increased the odds of VF before 2014 but this association was not statistically significant after 2014. Similarly, having started treatment with other regimens, reduced the likelihood of VF during 2014–2017 but not before. Finally, for CD4, the OR direction changed for being diagnosed with CD4 ≥200 cells/mm³, increasing marginally the odds of VF in the period 2014–2017 compared with 2008–2013 (See Table 3).

### Discussion

Based on 10 years of national data of PLWH in Mexico, this study has provided new information on the determinants of virologic failure and treatment success between 2008 and 2017 and clinical guideline changes for treatment initiation since 2014 eliminating the CD4 threshold previously established (CD4 ≤ 200 cells/mm³). Compared to the 2007–2013 period, individuals treated during 2014–2017 were younger, a higher proportion was male, more were initially treated in CAPASITS, a higher proportion were in the South of Mexico, and (as expected) with baseline CD4 was higher, compared to the period 2008–2013. The proportion of individuals with VF decreased from 50% in 2008–2013 to 33% in 2014–2017, suggesting that more adults were responding better to treatment. The multivariate analysis indicates that actions in 2014, eliminating the CD4 threshold for treatment initiation, reduced the odds of VF by 50%, after controlling for other variables. When analyzing VF by period, it was shown that being initially treated in another region than Mexico City or in a medium or highly deprived area was not a significant predictor of VF during 2014–2017. These could be explained by the national distribution of health facilities in the whole country which almost doubled from 2007 to 2013 and changes into a more integrated and centralized approach to HIV treatment and care in Mexico, including testing for all high and not high-risk population was expanded, the CD4, lowering the threshold for treatment initiation, and starting massive prevention campaigns as the result of the 2013 implementation of the National HIV plan.

It is difficult to compare our analysis with other studies conducted in Mexico given that this is the first study analyzing VF in these settings for all PLWH receiving care through the MoH. However, there is a governmental publication reporting that of all people enrolled in SALVAR living in Mexico City or the State of Mexico, 46.8% have acquired-resistance to efavirenz. Our results showing a higher likelihood of VF among female are consistent with the results showed by Mata-Marin et al. in a hospital in Mexico, who explained the findings because of a lower educational level and a higher probability of being unemployed for women as well as lower resources and social insurance to access ART compared to men. Regarding our findings for age, similar results were found in Latin American and Caribbean countries including Mexico, where the older population had a lower risk of VF, possibly explained by higher adherence, lower risk behaviors, and general awareness of better health care. Also, consistent with international literature, studies in Latin America and Africa, show that to initiate treatment with CD4 ≥200 cells/mm³ reduces the odds of VF. These effects could be explained because CD4 count at treatment initiation is a biologic predictor of a better immunological function and slower disease progression. However, our stratified analysis indicated that CD4 levels increase the odds of VF after 2013, but the association is marginal (OR of 1.08; 95% CI of 1.01–1.15). Although the association of CD4 levels and VF after 2014 is counterintuitive, it could be explained by a few reasons. First, as identified as one of our study limitations, SALVAR data do not include information on treatment adherence, which may create some bias. Second, in addition to eliminating in 2014 the CD4 threshold to initiate ART treatment, a year before other measures were implemented including diagnosis and awareness campaigns, increasing access to HIV care by targeting low-risk individuals could partially explain this result as we were not able to control for these unmeasured confounders. For example, it has been shown that individuals with a lower perception of risk have a poorer adherence which could
### Table 3. Multivariate logistic regression for virologic failure, 2008–2017.

| Variable                                      | Virologic failure | OR All periods | OR 2008–2013 | OR 2014–2017 |
|-----------------------------------------------|-------------------|----------------|--------------|--------------|
| **Period of treatment initiation (ref: before 2008–2013)** |                   |                |              |              |
| 2014–2017                                     |                   | 0.50** [0.487–0.517] |              |              |
| **Gender (ref: Female)**                      |                   |                |              |              |
| Male                                          | 0.88** [0.847–0.914] | 0.87** [0.829–0.919] | 0.86** [0.809–0.907] |              |
| Transgender                                   | 0.84              | 0.8            | 0.85         |              |

| [0.675–1.045] [0.585–1.086] [0.626–1.162] |
| **Age (ref: 18–29)**                         |                   |                |              |              |
| 30–39                                         | 0.91** [0.880–0.942] | 0.81** [0.772–0.852] | 1             |              |
| 40–49                                         | 0.78** [0.747–0.812] | 0.70** [0.657–0.737] | 0.86** [0.808–0.913] |              |
| 50–59                                         | 0.72** [0.680–0.770] | 0.66** [0.607–0.721] | 0.78** [0.709–0.851] |              |
| >60                                           | 0.72** [0.645–0.805] | 0.67** [0.626–0.774] | 0.77** [0.646–0.906] |              |

| **Region (ref: Mexico City)**                 |                   |                |              |              |
| Central East                                  | 1.48** [1.355–1.622] | 1.91** [1.702–2.142] | 0.83* [0.721–0.965] |              |
| Central West                                  | 1.76** [1.609–1.920] | 2.09** [1.867–2.334] | 1.09         |              |
| Northwest                                     | 2.13** [1.933–2.337] | 2.86** [2.528–3.230] | 1.14+        |              |
| Northeast                                     | 1.94** [1.756–2.150] | 2.79** [2.445–3.190] | 0.99         |              |
| South                                         | 1.76** [1.608–1.935] | 2.61** [2.315–2.939] | 0.89         |              |

| **Type of health facility (ref: hospital/National institute)** |                   |                |              |              |
| CAPASITS                                       | 1.09** [1.041–1.140] | 1.08* [1.013–1.149] | 1.14** [1.066–1.218] |              |
| Specialized clinic                             | 2.96** [2.723–3.225] | 3.48** [3.128–3.880] | 1.89** [1.652–2.172] |              |

| **Index of marginalization (ref: low)**         |                   |                |              |              |
| Medium                                         | 1.17+ [0.986–1.380] | 1.15           | 1.18        |              |
| High                                           | 0.90+ [0.810–1.010] | 0.83*          | 1.02        |              |

| **Viral load**                                 |                   |                |              |              |
| At treatment (ref: VL≤100,000 u/ml)            |                   |                |              |              |
| VL>100,000 u/ml                               | 1.50** [1.453–1.547] | 1.31** [1.257–1.371] | 1.73** [1.648–1.805] |              |
| **CD4**                                        |                   |                |              |              |
| At treatment (ref: CD4<200 cells/mm³)          |                   |                |              |              |
| CD4≥200 cells/mm³                              | 0.89** [0.849–0.937] | 0.68** [0.629–0.738] | 1.08* [1.011–1.149] |              |

| **Treatment options**                          |                   |                |              |              |
| ART (ref: EFV/FTC/TDF)                         |                   |                |              |              |
| EFV+ABC/3TC                                    | 1.22** [1.166–1.282] | 1.16** [1.077–1.245] | 1.34** [1.259–1.432] |              |
| Boosted PI                                     | 1.32** [1.260–1.381] | 1.34** [1.263–1.426] | 1.29** [1.203–1.387] |              |

(continued)
be the case for those PLWH with higher CD4 count (fewer symptoms and warning signs for disease progression).\textsuperscript{36,37} Besides the direct association of poor adherence and VF, intermittent ART adherence has also been associated with CD4 variability, which is also associated with VF.\textsuperscript{37} In contrast, lower VL levels at treatment initiation are associated with better prognosis and successful viral responses.\textsuperscript{32} This could be explained because VL is a predictor for disease progress. Patients with higher levels at treatment initiation presented a more complex and advanced disease than patients with lower levels.\textsuperscript{38,39} When observing the stratified analysis for VF, our results are similar to a previous analysis concerning Mexican regions and different periods.\textsuperscript{26} The effect of being treated in a region different than Mexico City losses significance after 2014. This could also be explained to changes in policies regarding diagnosis, where late testing is the main reason for a late and unsuccessful treatment,\textsuperscript{50} as well as an expansion of the Mexican health system.\textsuperscript{10} Compared to studies previously performed in Mexico around PLWH, our study gives information based on national-wide patient-data and evaluated changes in treatment initiation policies after modifications in international and national clinical guidelines.

Our study has some limitations. The analysis was constrained by the list of variables captured in SALVAR, which do not include possible confounders, such as employment situation, risk behaviors and access to HIV healthcare (e.g., some individuals in remote areas could never know their HIV status). Second, there was some missing information from 29,000 adults, which might not be random. However, we did not find any differences on gender, age or region between those with complete information and those without CD4 and VL measures. The data did not allow for capturing adherence to treatment, which could be a determinant of treatment success, and therefore VF.\textsuperscript{41,42} Some studies have shown that two of the main determinants of non-adherence are access to ART and financial constraints.\textsuperscript{43,44} However, the Mexican government started providing free treatment to all PLWH in 2003.\textsuperscript{40} Besides, to our knowledge, no widespread or national programs to improve adherence were implemented during the time of analysis. Therefore, we assumed that adherence rates did not change significantly from one period to another. Finally, the first line ART used for the analysis are mainly based on a backbone + EFV, which does not reflect current treatment options and ART use in Mexico where integrase inhibitors are the preferred ART option in clinical guidelines.\textsuperscript{35} However, this work presents the Mexican situation during 2008–2017 and evaluates the modification on national clinical guidelines after 2014. The findings of our study could also increase awareness, improvement of HIV-specific health care, and changes in treatment options by informing decision-makers about trends and outcomes of the current HIV program. Despite the limitations, our study has several strengths. We performed a national-wide analysis with a large sample of patient-data representing 64% of PLWH in Mexico and a long follow-up period. This is the first analysis studying determinants of virological failure in Mexico with this sample size and a 10 year study period.

Derived from our analysis, some hypotheses can be made. We identified key indicators and determinants of treatment success that could inform future policies and programs targeting PLWH in Mexico. Further research is required to evaluate the association between early treatment initiation, time from diagnosis to treatment, and virologic outcomes. Furthermore, this analysis highlights the need to record adherence in the SALVAR database for a deeper understanding of VF determinants.

**Conclusion**

This study indicates that, by removing threshold levels of CD4 required for treatment initiation in Mexico, combined with an expansion of ART access through provision of more clinics country-wide, a greater number of PLWH initiated treatment and fewer had virologic failure. Identifying sociodemographic determinants of VF could enhance policy development and facilitate the achievement of policy objectives, improving national indicators of the Mexican epidemic of HIV.

### Table 3. (continued)

| Variable | OR All periods | OR 2008–2013 | OR 2014–2017 |
|----------|----------------|--------------|--------------|
| Other    | 1.19\*\*       | 1.61\*\*     | 0.67\*\*     |
|          | [1.133–1.252]  | [1.240–1.399] | [0.621–0.741] |
| Constant | 0.62\*\*       | 0.76\*\*     | 0.37\*\*     |
|          | [0.534–0.717]  | [0.618–0.926] | [0.293–0.460] |
| Observations | 79,755         | 38,320       | 41,435       |
| C-Statistics | 0.6368         | 0.6144       | 0.6013       |

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \ *
Acknowledgments
The authors acknowledge to the Center for Aids Prevention and Control in Mexico (CENSIDA) the authorization to use the information for the analysis performed. Analyzed data is from an anonymized database.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Amilcar Azamar-Alonso https://orcid.org/0000-0002-0398-3896
Fiona Smaill https://orcid.org/0000-0002-1305-6260

Notes
1. The marginalization index is constructed by the Mexican government and reported by locality or municipality. The index is constructed through a principal component analysis (PCA) indicating the level of deprivation by geographical area. It includes aggregated socio-economic variables (at locality or municipal level) such as proportion of individuals older than 15 years old without elementary school, proportion of houses without drinking water, electricity, or cement floor (21).

References
1. Vermund SH. Control of HIV epidemic: improve access to testing and ART [Internet]. Lancet HIV 2017; 4(12): e533–e534. https://linkinghub.elsevier.com/retrieve/pii/S2352301817301662 (accessed 20 January 2021).
2. WHO. Viral suppression for HIV treatment success and prevention of sexual transmission of HIV [Internet]. Geneva: WHO, Departmental News, 2018. https://www.who.int/hiv/mediacentre/news/viral-suppression-hiv-transmission/en/ (accessed 11 March 2021).
3. May MT. Better to know: the importance of early HIV diagnosis [Internet]. Lancet Public Health 2017; 2(1): e6–e7. https://linkinghub.elsevier.com/retrieve/pii/S246826671630038X (accessed 11 March 2021).
4. Novelli S, Lécroux C, Avettand-Fenoel V, et al. Long-term therapeutic impact of the timing of antiretroviral therapy in patients diagnosed with primary human immunodeficiency virus type 1 infection [Internet]. Clin Infect Dis 2018; 66(10): 1519–1527. https://academic.oup.com/cid/article/66/10/1519/4683678 (accessed 11 March 2021).
5. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection [Internet]. N Engl J Med 2015; 373(9): 795–807. http://www.nejm.org/doi/10.1056/NEJMoa1506816 (accessed 21 October 2021).
6. UNAIDS. 90–90–90—An ambitious treatment target to help end the AIDS epidemic [Internet]. http://www.unaids.org/en/resources/documents/2014/90-90-90 (2014).
7. Gupta-Wright A, Fielding K, van Oosterhout JJ, et al. Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: An observational cohort study [Internet]. Lancet HIV 2020; 7(9): e620–e628. https://linkinghub.elsevier.com/retrieve/pii/S2352301820301727 (accessed 10 March 2021).
8. CNDH. Programa de acción específico 2007-2012 en respuesta al VIH/SIDA e ITS [Internet]. 2008. https://www.cndh.org.mx/sites/default/files/doce/Programas/VIH_OtrasPublicacionesdeinteresrelacionadodosenelVIH/CENSIDA/Programa%20Accion%202007_2012VIH_SIDA.pdf.
9. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach [Internet]. Geneva: World Health Organization. http://www.ncbi.nlm.nih.gov/books/NBK195400/ (2013, accessed 5 May 2021).
10. Secretaría de Salud. Programa de Acción Específica Respuesta al VIH, Sida e ITS 2013-2018 [Internet]. 2013. http://www.censida.salud.gob.mx/descargas/acerca/PAE_2013_2018_AUTORIZADA.pdf.
11. Secretaría de Salud. Centro Nacional para la Prevención y el Control del VIH/SIDA. Guía de Manejo Antirretroviral de las Personas con VIH. 6th ed. Mexico: Secretaría de Salud, 2014.
12. Magis-Rodríguez C, Bravo García E, Valenzuela Lara M, et al. Diez años monitoreando a los pacientes con VIH en México: el Sistema SALVAR del Censida. CENSIDA (Boletín Salvar). México: Secretaría de Salud, 2018.
13. CENSIDA. Boletín de atención integral de personas que viven con VIH en México [Internet]. 2020. https://www.gob.mx/cms/uploads/attachment/file/577447/Boletin_n_DAI_2DO_TRIM.pdf.
14. Crabtree-Ramírez B, Villasis-Keever A, Galindo-Fraga A, et al. Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico. AIDS Res Hum Retroviruses 2010; 26(4): 373–378. DOI: 10.1089/aid.2009.0077.
15. Secretaría de Gobernación. NORMA Oficial Mexicana NOM-010-SSA2-2010. Para la prevención y el control de la infección por Virus de la Inmunodeficiencia Humana [Internet]. México: Secretaría de Gobernación, 2010. http://doi.gob.mx/nota_detalle.php?codigo=5166864&fecha=10/11/2010.
16. CENSIDA. Boletín de atención integral de personas con VIH 2018 [Internet]. 2018. https://www.gob.mx/cms/uploads/attachment/file/513720/RN_D_Mundial_sida_2018.pdf.
17. CENSIDA. Guía de Manejo Antirretroviral de las Personas con VIH [Internet]. 2020. https://www.gob.mx/cms/documentos/guia-de-manejo-antirretroviral-de-las-personas-con-vih.
18. Mesic A, Spina A, Mar HT, et al. Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: Retrospective cohort analysis [Internet]. AIDS Res Ther 2021; 18(1): 16. https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-021-00336-0 (accessed 15 July 2021).
19. The SPARTAC Trial Investigators. Short-course antiretroviral therapy in primary HIV infection [Internet]. N Engl J Med 2013; 368(3): 207–217. http://www.nejm.org/doi/10.1056/NEJMoa1110039 (accessed 5 May 2021).
20. Bautista-Arredondo S, Colchero MA, Romero M, et al. Is the HIV epidemic stable among MSM in Mexico? HIV prevalence and risk behavior results from a nationally representative survey among men who have sex with men [Internet]. PLoS
372

International Journal of STD & AIDS 33(4)

One 2013; 8(9): e72616. https://dx.plos.org/10.1371/journal. pone.0072616 (accessed 26 December 2019)

21. CONAPO. Índice de Marginalización por localidad 2010 [Internet]. 2010. http://www.conapo.gob.mx/work/models/CONAPO/ indices_marginales2010/documentoprinicional/Contenido_03.pdf.

22. Fox MP, Sanne IM, Conradie F, et al. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μL is associated with improved treatment outcomes in South Africa [Internet]. AIDS 2010; 24(13): 2041–2050. http://journals.lww. com/00002030-20100824-00008 (accessed 25 January 2021).

23. Stephan C, Hill A, Sawyer W, et al. Impact of baseline HIV-1 RNA levels on initial high active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*: HAART response at high baseline viral loads [Internet]. HIV Med 2013; 14(5): 284–292. DOI: 10.1111/hiv.12004

24. CENSIDA. Panorama de la respuesta nacional al VIH 2015. Mexico. 2015.

25. Muguvevo MJ, Castellano C, Edelman D, et al. Late diagnosis of HIV infection: the role of age and sex [Internet]. Am J Med 2007; 120(4): 370–373. https://linkinghub.elsevier.com/retrieve/pii/S0002934306006760 (accessed 28 December 2019)

26. Alonso AA, Bautista-Arredondo SA, Smaill F, et al. Patient characteristics and determinants of CD4 at diagnosis of HIV in Mexico from 2008 to 2017: a 10-year population-based study [Internet]. AIDS Res Ther 2020; 18: 84. https://www.researchsquare.com/article/rs-104632/v1 (accessed 11 March 2021).

27. CENSIDA. Boletín de atención integral de personas que viven con VIH en México [Internet]. 2021. https://www.gob.mx/cms/uploads/attachment/file/626488/Boletin_de_Atencion_integral_de_Personas_con_VIH__CENSIDA.pdf.

28. Jose Antonio M-M. Clinical and epidemiological differences between women and men with HIV infection in Mexico [Internet]. J AIDS Clin Res 2016; 7(3): 551. https://www.omicsone.org/open-access/clinical-and-epidemiological-differences-between-women-and-men-withhiv-infection-in-mexico-2155-6113-1000551.php?aid=69810 (accessed 20 January 2021)

29. Carriquiry G, Giga NT, Castillo JL, et al. Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean Cohort [Internet]. J Int AIDS Soc 2018; 21(3): e25088. http://doi.wiley.com/10.1002/jia2.25088 (accessed 20 January 2021).

30. Cesar C, Jenkins CA, Shepherd BE, et al. Incidence of virologic failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: An observational cohort study [Internet]. Lancet HIV 2015, 2(11): e492–e500. https://linkinghub.elsevier.com/retrieve/pii/S2352301815001836 (accessed 20 January 2021).

31. Wolff MJ, Cortes CP, Mejia FA, et al. Evaluating the care cascade after antiretroviral therapy initiation in Latin America [Internet]. Int J STD AIDS 2018; 29(1): 4–12. http://journals.sagepub.com/doi/10.1177/0956462417714094 (accessed 21 January 2021).

32. Silveira MPT, Silveira CPT, Guttier MC, et al. Long-term immune and virologic response in HIV-infected patients receiving antiretroviral therapy [Internet]. J Clin Pharm Ther 2016; 41(6): 689–694. http://doi.wiley.com/10.1111/jcpt.12450 (accessed 21 January 2021).

33. Hawkins C, Ulenga N, Liu E, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults [Internet]. J Antimicrob Chemother 2016; 71(7): 1966–1974.

34. Kiweewa F, Esber A., Musingye E., et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study [Internet]. PLoS ONE 2019; 14(2): e0211344. https://dx.plos.org/10.1371/journal.pone.0211344 (accessed 21 January 2021)

35. Agegnehu CD, Merid MW and Yenit MK. Incidence and predictors of virological failure among adult HIV patients on first-line antiretroviral therapy in Amhara regional referral hospitals; Ethiopia: A retrospective follow-up study [Internet]. BMC Infect Dis 2020; 20(1): 460. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05177-2 (accessed 21 January 2021)

36. Corneli A, Wang M, Agot K, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP [Internet]. J Acquir Immune Defic Syndr 2014; 67(5): 555–563. https://journals.lww.com/00126334-20141215-00014 (accessed 22 October 2021)

37. Stirrup OT, Sabin CA, Phillips AN, et al. Associations between baseline characteristics, CD4 cell count response and virological outcome on first-line efavirenz + tenofovir + emtricitabine for HIV [Internet]. J Virus Erad 2019; 5(4): 204–211. https://linkinghub.elsevier.com/retrieve/pii/S2055664020300376 (accessed 22 October 2021)

38. Mellors JW. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection [Internet]. Ann Intern Med [Internet] 1997; 126(12): 946. http://annals.org/article. aspx?doi=10.7326/0003-4819-126-12-199706150-00003 (accessed 22 October 2021)

39. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection [Internet]. J Acquir Immune Defic Syndr 2002; 29(4): 346–355. http://journals.lww. com/00126334-200204010-00004 (accessed 22 October 2021)

40. Hemández-Romieu AC, del Rio C, Hernández-Ávila JE, et al. CD4 counts at entry to HIV care in mexico for patients under the “universal antiretroviral treatment program for the uninsured population” [Internet]. PLoS One 2016; 11(3): e0152444. https://dx.plos.org/10.1371/journal.pone.0152444 (accessed 25 December 2019)

41. Beazhbe WM, Chalmers L, Bereznicki LR, et al. Adherence to antiretroviral therapy and virologic failure: a meta-analysis [Internet]. Medicine (Baltimore) 2016; 95(15): e3361. http://journals.lww.com/00005792-201604120-00058 (accessed 25 January 2021).

42. Emanzadeh-Fard SFard E.S, SeyedAlinaghi S and Paydary K. Adherence to antiretroviral therapy and virologic failure: a meta-analysis [Internet]. Medicine 2015; 29(4): e19771. http://www.eurekaselect.com/ content.php?genre=article&issn=1871-5265& volume=12&issue=5&spage=346 (accessed 25 January 2021)

43. Paramesha A and Chacko L. Predictors of adherence to antiretroviral therapy among people living with HIV [Internet]. North
45. Secretaría de Salud. Guía de manejo antirretroviral de las personas con VIH [Internet]. 10ma edición. Mexico: Secretaría de Salud, 2019. https://www.gob.mx/cms/uploads/attachment/file/525919/GUIA_DE_MANEJO_ANTIRRETROVIRAL_DE_LAS_PERSONAS_CON_VIH_2019_-_VERSION_COMPLETA1.pdf